Tags : Gene Therapies

Takeda Collaborates with Carmine for Non-Viral Gene Therapies Worth Up

Shots: The two companies signed a research agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine’s REGENT technology, based on red blood cell extracellular vesicles (RBCEV) Carmine to receive upfront, research funding, up to $900M milestones along with royalties on sales of therapies. Following the completion of […]Read More

Takeda Collaborates with Codexis to Advance Novel Gene Therapies for

Shots: Codexis to receive an upfront payment, reimbursement for research and development fees, development and commercial milestones along with royalties on sales of any commercial product developed under the collaboration The alliance will initially work on three programs to develop novel gene therapies for lysosomal storage disorders and blood factor deficiencies. Codexis will create the […]Read More

Biogen Signs an Exclusive Worldwide License Agreement with Sangamo to

Shots: Sangamo to receive $350 million upfront, including $125M license fee & $225M equity investment in Sangamo’s stock or ~24M shares at $9.21/share and is eligible to receive $2.37B as milestones along with royalties on sales of the therapies Biogen to get an exclusive WW right of ST-501 for tauopathies including AD, ST-502 for synucleinopathies […]Read More

Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne

Shots: The JV leverages the expertise of three companies that includes Wilson Wolf’s G-Rex technology, BioTechne’s proteins, reagents, media, and gene-editing technologies and Fresenius Kabi’s Lovo cell processing system washes, concentrates and harvests cells The JV focus on providing scalable manufacturing technologies and processes required to develop and commercialize new cell and gene therapies. All […]Read More

Sarepta Signs a License Agreement with Stride Bio to Develop

Shots: The companies collaborated to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets. StrideBio will be responsible for research, development and manufacturing of the first four CNS targets which include MECP2 (Rett syndrome), SCN1A (Dravet syndrome), UBE3A (Angelman syndrome), and NPC1 (Niemann-Pick) Stride Bio to receive $48M upfront […]Read More

REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based

Shots: REGENXBIO plans to construct a cGMP manufacturing facility in Rockville, Maryland to produce gene therapy vectors based on NAV technology at scales up to 2,000L using its platform suspension cell culture process The addition of new cGMP manufacturing facility complements current external manufacturing capabilities, enabling a supply of NAV vectors from both internal and […]Read More

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene

 Shots: StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three […]Read More

Merck KGaA Collaborates with GenScript for the Expansion of Cell

Shots: Merck KGaA & GenScript enter into a collaboration agreement to accelerate the industrialization and commercialization of cell and gene therapy in China. Merck to provide products, services & staff training from lab development to large-scale GMP manufacturing to GenScript The focus of the collaboration is to develop a global platform for plasmid and virus […]Read More